5 completed, 5 unknown, 3 recruiting, 2 not yet recruiting. 20 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 20 | Completed 5, Unknown 5, Recruiting 3, Not yet recruiting 2, Terminated 2, Withdrawn 2, Active not recruiting 1 |
Follow Lenalidomide: new trials by email Literature Review of Lenalidomide trials Research Report on Lenalidomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen Sotoclax, Carfilzomib, Lenalidomide - Newly Diagnosed Multiple Myeloma, T(11;14) | Phase 4 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 20 | 2026-07-01 | 2026-07-17 |
| Isa-VRD in TIE HRMM Isatuximab, bortezomib, lenalidomide, dexamethason, Bortezomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 117 | 2026-01-30 | 2026-01-13 |
| Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM) Bortezomib + Lenalidomide + Dexamethasone + Fenofibrate 160 mg tablet, Bortezomib + Lenalidomide + Dexamethasone - Peripheral Neuropathy, Multiple Myeloma, Neoplasms | Phase 4 | Recruiting | Tanta University | 44 | 2025-08-30 | 2025-11-04 |
| Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection Carfilzomib, Daratumumab, Lenalidomide - Newly Diagnosed, High Risk | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 59 | 2024-06-12 | 2025-06-12 |
| Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS Lenalidomide, Azacitidine - Myelodysplastic Syndromes | Phase 4 | Unknown | Peking Union Medical College Hospital | 138 | 2023-08-01 | 2023-08-22 |
| Immunomodulators on HIV-1 Reservoir Lenalidomide, Adenosylmethionine - HIV Infections | Phase 4 | Unknown | First Affiliated Hospital of Zhejiang University | 48 | 2022-11-20 | 2023-09-14 |
| Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma Ixazomib plus low-dose lenalidomide, Ixazomib - Multiple Myeloma | Phase 4 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2022-07-01 | 2026-01-05 |
| A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma Ixazomib, Pomalidomide, Lenalidomide - Multiple Myeloma | Phase 4 | Withdrawn | Takeda | 2022-06-30 | 2022-05-03 | |
| Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5., Placebo - COVID-19 | Phase 4 | Unknown | Hospital Universitario Getafe | 120 | 2020-10-27 | 2020-07-31 |
| Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Bortezomib 3.5 MG - Newly Diagnosed Multiple Myeloma | Phase 4 | Withdrawn | Al-Rasheed University College | 2020-03-01 | 2023-04-28 | |
| Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients Ixazomib, Lenalidomide - Multiple Myeloma | Phase 4 | Completed | Peking Union Medical College Hospital | 211 | 2019-09-24 | 2024-08-01 |
| Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide + Dexamethasone - Relapsed Refractory Multiple Myeloma | Phase 4 | Completed | Amgen | 101 | 2019-09-16 | 2026-05-11 |
| PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine - Peripheral T-cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 100 | 2019-09-01 | 2020-05-12 |
| PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma PD-1 Antibody, chidamide, lenalidomide and etoposide - NK/T Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 50 | 2019-04-01 | 2019-07-30 |
| STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA Velcade, Melphalan, Prednisone - Multiple Myeloma | Phase 4 | Active not recruiting | University of Turin, Italy | 450 | 2019-01-03 | 2025-12-03 |
| A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Ixazomib, Bortezomib, Carfilzomib - Relapsed and/or Refractory Multiple Myeloma | Phase 4 | Completed | Takeda | 45 | 2018-02-18 | 2022-09-27 |
| A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) Ixazomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Terminated | Takeda | 141 | 2017-11-13 | 2026-05-04 |
| Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Completed | Columbia University | 60 | 2012-09-01 | 2020-02-05 |
| LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Lenalidomide - AML | Phase 4 | Terminated | PETHEMA Foundation | 4 | 2011-01-01 | 2014-04-07 |
| Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Lenalidomide - Cutaneous Lupus | Phase 4 | Completed | Hospital Universitari Vall d'Hebron Research Institute | 15 | 2010-01-01 | 2011-08-03 |
Multiple Myeloma (10) · COVID-19 (1) · HIV Infections (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Peripheral Nervous System Diseases (1)
Peking Union Medical College Hospital (3) · Takeda (3) · Mingzhi Zhang (2) · The First Affiliated Hospital of Soochow University (2) · Al-Rasheed University College (1) · Amgen (1) · Columbia University (1) · First Affiliated Hospital of Zhejiang University (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Hospital Universitario Getafe (1) · PETHEMA Foundation (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Tanta University (1) · University of Turin, Italy (1)
China (9) · Spain (3) · United States (2) · Egypt (1) · India (1) · Iraq (1) · Italy (1) · Japan (1)
Adil S Al-Oqaby, PhD (1) · Alaaldin S Naji, PhD (1) · Ali M Jawad, PhD (1) · Ammer F Majid, PhD (1) · Ashraf M Alaa, BSc of clinical pharmacy (1) · Bassam F Matti, PhD (1) · Biao Zhu (1) · Hawraa D Jumaa, PhD (1) · Hayder A Fawzi, PhD (1) · Joaquin De Haro, MD (1) · Junling Zhuang (1) · Junling Zhuang, MD (1)
PMID 23217273, PMID 37341778, PMID 37807952
2009 (1)